To prove that LB100 sensitised tumour cells to ICB therapies regardless of its Treg inhibitory activity, we showed the expression of p110δ in Treg (Foxp3+), but not in CD8+ or polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) (Ly6Ghigh) in the CT26 tumour microenvironment (Supplementary Fig. 8). The gene discussed is FOXP3; the disease is neoplasm.